Big enough for an aromatase inhibitor? How adiposity affects male fertility.

Abstract

Obesity is a pandemic and is associated with multiple medical problems including subfertility. Male obesity has been associated with altered semen parameters and reproductive hormonal levels, including a reduced testosterone:estradiol (T:E₂) ratio. Treatment methods employed for obesity-related male subfertility include gonadotropin administration, weight loss, and aromatase inhibitors. Letrozole is a highly effective nonsteroidal aromatase inhibitor that has been used to treat male subfertility in several case series with promising results. Adequately designed randomized controlled studies are needed to produce evidence-based data on the role of aromatase inhibitors in male subfertility management and evaluate the side-effect profile.

• Authors: Sahar M Stephens, Alex J Polotsky
• Journal: Seminars in reproductive medicine (Semin Reprod Med) Vol. 31 Issue 4 Pg. 251-7 (Jul 2013) ISSN: 1526-4564 [Electronic] United States
• PMID: 23775380 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
• Copyright: Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Chemical References

• Aromatase Inhibitors
• Nitriles
• Triazoles
• Letrozole

Topics

• Adiposity
• Aromatase Inhibitors (therapeutic use)
• Evidence-Based Medicine
• Humans
• Infertility, Male (complications, drug therapy, etiology, physiopathology)
• Letrozole
• Male
• Nitriles (therapeutic use)
• Obesity (physiopathology)
• Severity of Illness Index
• Triazoles (therapeutic use)